Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Galectin Therapeutics (NASDAQ:GALT) reported Q2 2026 results for the three months ended June 30, 2026 and said it reached agreement with the FDA on Phase 3 belapectin trial elements for MASH cirrhosis and portal hypertension, targeting protocol submission in 3Q 2026. Cash was $13.2M; net loss was $9.2M ($0.14/share). Chairman Uihlein converted about $105.8M debt into 34.4M shares.
How this was made
The 30-second read
Why it matters
The key new decision point is regulatory alignment with the FDA on Phase 3 trial design elements and the company’s stated plan to submit the registrational protocol in 3Q 2026. Separately, the debt conversion by the chairman reduces debt and accrued interest but increases share count.
Market read
Traders can frame this as a regulatory-path de-risking catalyst plus a capital-structure event, with the next major operational milestone being the Phase 3 protocol submission in 3Q 2026.
What to watch
The company reports a net loss and relies on a chairman-provided line of credit plus debt-to-equity conversion, which can pressure the stock via dilution even if the balance sheet improves.
Background
Galectin Therapeutics is developing belapectin (galectin-3 inhibitor) for MASH cirrhosis with portal hypertension, with a Phase 2b/3 NAVIGATE program feeding into a planned registrational Phase 3.
Ticker impact
Galectin says it reached agreement with the FDA on Phase 3 belapectin trial design for MASH cirrhosis and plans to submit the protocol in 3Q 2026.
Likely positive bias for near-term trading into 3Q 2026 protocol submission, with volatility tied to capital structure and ongoing trial readouts.
The article discloses a specific FDA agreement on Phase 3 elements and a stated timing target for protocol submission, which typically improves probability-weighted outcomes for biotech development-stage names.
Market effects
Reinforces FDA willingness to accept specific endpoints and centralized endoscopy review approaches in MASH cirrhosis/portal hypertension trials.
Limited direct regional spillover; primarily US biotech regulatory and clinical-trial sentiment.
EASL and journal publications cited may support broader scientific validation, but the tradable catalyst is the US FDA path alignment.
Counterpoint
FDA agreement does not guarantee Phase 3 success; investors may still discount the probability of achieving the composite liver outcome and varices-related endpoints.
Key entities
- companyGalectin Therapeutics, Inc.
NASDAQ-listed developer of belapectin for MASH cirrhosis and portal hypertension; reports FDA alignment and 3Q 2026 protocol submission plans.
- drug_programBelapectin
Galectin-3 inhibitor carbohydrate drug; Phase 3 registrational protocol planned for MASH cirrhosis with portal hypertension.
- regulatorU.S. Food and Drug Administration (FDA)
Agreed on key Phase 3 trial design elements and regulatory path forward for belapectin.
- executiveJoel Lewis
CEO and President who stated FDA alignment and timing for Phase 3 protocol submission.
- insiderRichard E. Uihlein
Chairman who converted approximately $105.8 million of debt and accrued interest into common stock effective July 31, 2026.
